Screener
Iovance Biotherapeutics, Inc. IOVA US — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Iovance Biotherapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 9:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091716
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| United States | $98,967 | $58,605 | $169,439 | $107,125 |
| Rest of world | 346 | 1,347 | 1,304 | 2,151 |
| Net revenue | $99,313 | $59,952 | $170,743 | $109,276 |
Item 1.Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Iovance Biotherapeutics, Inc.'s US — revenue?
- Iovance Biotherapeutics, Inc. (IOVA) reported US — revenue of $98.97M in Q2 2026.
- How has Iovance Biotherapeutics, Inc.'s US — revenue changed year-over-year?
- Iovance Biotherapeutics, Inc.'s US — revenue increased by 68.9% year-over-year, from $58.61M to $98.97M.
- What does US — revenue mean?
- This metric represents the total gross revenue generated from the sale of pharmaceutical products and services within the United States market, net of any assessed taxes. It serves as a primary indicator of the company's commercial success and market penetration for its therapeutic offerings in the domestic region. Tracking this figure allows investors to evaluate the adoption rate and revenue growth trajectory of the company's clinical-stage assets as they transition into commercialized products.
Ask your AI about Iovance Biotherapeutics, Inc.'s us — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude